$24.77
Value $692M
FLGT and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$24.77
Value $692M
$266.44
Value $642B
Fulgent Genetics (FLGT) has a market value of $692M and Johnson & Johnson (JNJ) $642B. Over the last year, with dividends, FLGT moved -14.9% and JNJ +36.2%. Dividend yield: FLGT none, JNJ 1.98%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
FLGT$692M
JNJ$642B
JNJ is 928 times FLGT
Revenue, 12 months
FLGT$330M
JNJ$99.3B
JNJ is 301 times FLGT
Net income, 12 months
FLGT-$91M
JNJ$16.1B
Operating margin
FLGT-39.2%
JNJ–
ROIC
FLGT-9.7%
JNJ12.4%
22.1 points apart
P/E
FLGT–
JNJ39.9
Dividend yield
FLGT0.0%
JNJ2.0%
2.0 points apart
5-year return
FLGT-73.5%
JNJ+88.6%
162.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
FLGT-73.5%
JNJ+88.6%
| Period | FLGTWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | -14.9%Price -14.9% | +36.2%Price +33.2% |
| 3 years since November 17, 2023 | -8.5%-2.9% a yearPrice -8.5% | +93.7%+24.6% a yearPrice +77.9% |
| 5 years since November 18, 2021 | -73.5%-23.3% a yearPrice -73.5% | +88.6%+13.5% a yearPrice +64.0% |
| 10 years since November 21, 2016 | +178.6%+10.8% a yearPrice +178.6% | +201.9%+11.7% a yearPrice +131.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
FLGTFulgent GeneticsJNJJohnson & Johnson
| Price | $24.77 | $266.44 |
|---|---|---|
| Market value | $692M | $642B |
| Enterprise value (EV) | $401M | $670B |
| P/E | – | 39.9 |
| P/E, 5-year median | – | 21.9 |
| P/B | 0.7 | 7.9 |
| EV/EBIT | – | 37.8 |
| Free cash flow yield | – | 3.2% |
| Revenue, 12 months | $330M | $99.3B |
|---|---|---|
| Net income, 12 months | -$91M | $16.1B |
| Free cash flow, 12 months | -$1.4M | $20.6B |
| Earnings per share, 12 months | -$2.91 | $6.59 |
| Revenue growth, year on year | 13.8% | 6.1% |
| Revenue growth a year, past | -5.2%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 33.8% | 67.6% |
|---|---|---|
| Operating margin | -39.2% | – |
| Net margin | -27.5% | 16.2% |
| ROIC | -9.7% | 12.4% |
| ROE | -8.6% | 19.7% |
| Cash | $293M | $17.2B |
|---|---|---|
| Total debt | $10M | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | -1,307.9× | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 1.6% | 0.9% |
| Shareholder yield | 1.6% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($642B) is about 927.8 times Fulgent Genetics ($692M), at today's prices.
Since November 21, 2016, FLGT's price moved +178.6% and JNJ's +131.7%. With dividends: FLGT +178.6% (+10.8% a year), JNJ +201.9% (+11.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Fulgent Genetics and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was -27.5% for Fulgent Genetics and 16.2% for Johnson & Johnson, and the operating margin -39.2% and –. Revenue was $330M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.